Literature DB >> 2924405

Phenobarbital promotion in diethylnitrosamine-initiated infant B6C3F1 mice: influence of gender.

C M Weghorst1, J E Klaunig.   

Abstract

Phenobarbital (PB) promotes hepatic tumorigenesis when chronically administered to male B6C3F1 mice after initiation with diethylnitrosamine (DENA) at 30 days of age. In contrast, when male B6C3F1 mice were initiated with DENA at 15 days of age, an inhibition of hepatic tumorigenesis occurred. The present study was undertaken to evaluate the influence of gender on the inhibiting ability of PB in the 15 day old DENA-initiated B6C3F1 mouse. Mice were injected with either DENA (5 micrograms/g) or saline at 15 days of age. At weaning mice were given either PB (500 p.p.m.) containing drinking water or deionized drinking water for 24 weeks. Male mice treated with DENA and PB demonstrated a significant decrease in the number of hepatocellular adenomas compared to males receiving DENA only. In contrast, females exposed to DENA and PB exhibited an enhancement of hepatic adenoma number compared to those receiving only DENA. In an additional experiment, individual preneoplastic foci from male and female B6C3F1 mice initiated with DENA at 15 days of age were examined for their responsiveness to the mitogenic stimuli of PB. Mice were exposed to either PB-containing or PB-free drinking water for 7 days. In non-PB treated males and females, preneoplastic hepatocytes demonstrated higher rates of DNA synthetic labelling compared to normal hepatocytes with no gender difference noted. Males exposed to PB exhibited increased levels of DNA synthesis in normal cells but not in preneoplastic foci. Females treated with PB, however, demonstrated significant increases in DNA synthesis in both preneoplastic and normal hepatocytes compared to non-PB treated females and PB-treated males. These findings suggest that in male mice initiated with DENA at 15 days of age, the preneoplastic foci are refractory to the proliferative effects of PB which may account for the observed inhibition of hepatic tumorigenesis by PB in this mouse strain.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2924405     DOI: 10.1093/carcin/10.3.609

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

Review 1.  Human relevance of rodent liver tumour formation by constitutive androstane receptor (CAR) activators.

Authors:  Brian G Lake
Journal:  Toxicol Res (Camb)       Date:  2018-03-12       Impact factor: 3.524

2.  Inhibitory effect of sialoadenectomy on hepatocellular tumourigenesis in male mice induced by 3'-methyl-4-dimethylaminoazobenzene.

Authors:  R Yamamoto; H Iishi; M Tatsuta; M Tsuji; N Terada
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

Review 3.  Experimental mouse models for hepatocellular carcinoma research.

Authors:  Femke Heindryckx; Isabelle Colle; Hans Van Vlierberghe
Journal:  Int J Exp Pathol       Date:  2009-08       Impact factor: 1.925

4.  An autoradiographic study of cellular proliferaton, DNA synthesis and cell cycle variability in the rat liver caused by phenobarbital-induced oxidative stress: the protective role of melatonin.

Authors:  Gamal H El-Sokkary
Journal:  Cell Mol Biol Lett       Date:  2007-02-12       Impact factor: 5.787

5.  Selective induction of DNA synthesis in mouse preneoplastic and neoplastic hepatic lesions after exposure to phenobarbital.

Authors:  J E Klaunig
Journal:  Environ Health Perspect       Date:  1993-12       Impact factor: 9.031

6.  Suppression by oestrogen of hepatocellular tumourigenesis induced in mice by 3'-methyl-4-dimethylaminoazobenzene.

Authors:  R Yamamoto; M Tatsuta; N Terada
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

7.  Correlation between serum prolactin levels and hepatocellular tumorigenesis induced by 3'-methyl-4-dimethylaminoazobenzene in mice.

Authors:  R Yamamoto; H Iishi; M Tatsuta; T Yamamoto; K Koike; Y Kanda; A Miyake; M Tsuji; N Terada
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.